Makena by the numbers

Even with the price reduction it announced last Friday, KV Pharmaceutical Co. is asking the U.S. healthcare system, including cash-strapped Medicaid programs, to pay a substantial premium for an FDA-approved version of hydroxyprogesterone caproate compared with products available from compounding pharmacies.